Health
Novel breast cancer therapy candidate enters clinical study – Mirage News
Kiran Dhillon In a UW Medicine cancer immunotherapy lab, research scientist Nick Drovetto puts a rack of samples into a liquid nitrogen tank. A Phase 1…
A Phase 1 patient trial of the novel, oral therapy candidate, Alpha TEA, for advanced HER2 positive breast cancer is now underway. Veana Therpeutics, Inc., and UW Medicine will collaborate on the clinical testing of Veana’s lead agent – an alpha TEA lysine salt, in combination with the monoclonal antibody, trastuzumab, brand name Herceptin.
In HER2 positive breast cancer, the tumor cells produce a higher-than-usual level of the HER2protein that drives cancer growth and spread.
Alpha TEA lysine…
-
Noosa News12 hours agoReubhan Ralph identified as man behind terrifying childcare centre incident in Peregian Springs on the Sunshine Coast
-
General10 hours agoPolice say new leads being pursued after baby’s body found in Alexander Heights stormwater drain
-
Noosa News20 hours agoInquest into Rosemarie Campbell’s death three days after gastric bypass surgery hears of ‘massive loss’ to family
-
General18 hours agoQueensland announced as 2027 Women’s Softball World Cup host in first Australian event since 1965